Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Xin Chen, PhD

Title(s)Professor, Bioengineering
SchoolSchool of Pharmacy
Phone415-502-6526
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    1991First Prize Award, Beijing Medical University, Beijing, China
    1998Postdoctoral Fellowship Award, Life Science Research Foundation, Baltimore, MD

    Collapse Overview 
    Collapse Overview
    My lab studies molecular genetics and signaling pathways during hepatic carcinogenesis. Specifically, using genomic approaches including expression arrays and array based CGH, we have identified large numbers of genes which are deregulated during liver cancer development. Using murine models, we are studying how these genetic alterations contribute to malignant transformation and progression in vivo. Our current studies focus on AKT/mTOR and Notch pathways and how they regulate cancer metabolism and cancer cell proliferation. In addition, using the novel mouse models as preclinical models, we are testing the therapeutic potentials of PI3K/mTOR or Notch inhibitors in treating liver cancers.

    Collapse Research 
    Collapse Research Activities and Funding
    Cabozentinib based combination therapy for the treatment of hepatocellular carcinoma
    NIH/NCI R03CA249236Apr 1, 2020 - Mar 31, 2022
    Role: Principal Investigator
    Signaling pathways during hepatocarcinogenesis
    NIH/NCI R01CA239251Mar 1, 2020 - Feb 28, 2025
    Role: Principal Investigator
    Role of Cancer-Associated Fibroblasts in Cholangiocarcinoma
    NIH/NCI R01CA228483Jun 19, 2018 - May 31, 2023
    Role: Co-Principal Investigator
    SWI/SNF complex in mouse HCC development
    NIH/NCI R03CA208215Aug 1, 2017 - Jul 31, 2019
    Role: Principal Investigator
    Inducible systems for studying liver tumor mainenance in vivo
    NIH/NCI R03CA208311Jul 1, 2017 - Jun 30, 2019
    Role: Principal Investigator
    Signaling cascades in cholangiocarcinoma development
    NIH/NCI R01CA190606Apr 5, 2016 - Mar 31, 2021
    Role: Principal Investigator
    Yap and beta-catenin interactions in liver: Implications in Pathophysiology
    NIH/NCI R01CA204586Apr 5, 2016 - Mar 31, 2021
    Role: Co-Principal Investigator
    Glutamine catabolism in c-Myc driven liver tumor development
    NIH/NCI R21CA198490Jun 1, 2015 - May 31, 2017
    Role: Principal Investigator
    Fatty acid transporters in cholangiocarcinoma pathogenesis
    NIH/NCI R21CA187306Jul 1, 2014 - Jun 30, 2016
    Role: Principal Investigator
    Lipogenic inhibitors in prevention of oncogene induced liver cancer
    NIH/NCI R03CA165122Mar 1, 2012 - Feb 28, 2014
    Role: Principal Investigator
    Virus-gene interactions during hepatic carcinogenesis
    NIH/NCI R21CA158508Sep 12, 2011 - Aug 31, 2014
    Role: Principal Investigator
    Genetic Alterations Promoting Alcohol Induced Hepatic Carcinogenesis
    NIH/NIAAA R21AA020078Sep 1, 2011 - Aug 31, 2014
    Role: Principal Investigator
    Targeted siRNA Delivery to Liver with EIT guided Sonoporation
    NIH/NIAAA R43AA019638Sep 30, 2009 - Mar 31, 2011
    Role: Co-Principal Investigator
    Molecular Genetics of Liver Cancers
    NIH/NCI R01CA136606May 1, 2009 - Feb 28, 2014
    Role: Principal Investigator
    A flexible somatic and sporadic mouse model for liver cancers
    NIH/NCI R21CA131625Jul 1, 2008 - Jun 30, 2011
    Role: Principal Investigator
    Expression Programs of Intestinal Cell Differentiation
    NIH/NIDDK R21DK069309Sep 15, 2005 - Aug 31, 2008
    Role: Principal Investigator
    Hedgehog signaling in human hepatocellular carcinoma
    NIH/NCI R21CA113393Jul 1, 2005 - Jun 30, 2008
    Role: Principal Investigator
    Expression patterns of gastric premalignant lesions
    NIH/NCI R03CA112638Sep 30, 2004 - Aug 31, 2007
    Role: Principal Investigator
    Gene Expression Profiles in Human Liver Cancers
    NIH/NCI K01CA096774Sep 11, 2003 - Aug 31, 2009
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wang J, Dong M, Xu Z, Song X, Zhang S, Qiao Y, Che L, Gordan J, Hu K, Liu Y, Calvisi DF, Chen X. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene. 2018 06; 37(24):3229-3242. PMID: 29545603.
      View in: PubMed
    2. Zhang S, Wang J, Wang H, Fan L, Fan B, Zeng B, Tao J, Li X, Che L, Cigliano A, Ribback S, Dombrowski F, Chen B, Cong W, Wei L, Calvisi DF, Chen X. Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans. Am J Pathol. 2018 04; 188(4):995-1006. PMID: 29378174.
      View in: PubMed
    3. Dong M, Liu X, Evert K, Utpatel K, Peters M, Zhang S, Xu Z, Che L, Cigliano A, Ribback S, Dombrowski F, Cossu A, Gordan J, Calvisi DF, Evert M, Liu Y, Chen X. Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death Dis. 2018 01 18; 9(2):31. PMID: 29348467.
      View in: PubMed
    4. Xu Z, Hu J, Cao H, Pilo MG, Cigliano A, Shao Z, Xu M, Ribback S, Dombrowski F, Calvisi DF, Chen X. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. Exp Mol Med. 2018 01 05; 50(1):e417. PMID: 29303510.
      View in: PubMed
    5. Jia J, Qiao Y, Pilo MG, Cigliano A, Liu X, Shao Z, Calvisi DF, Chen X. Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade. PLoS One. 2017; 12(9):e0184068. PMID: 28877210.
      View in: PubMed
    6. Liu P, Calvisi DF, Kiss A, Cigliano A, Schaff Z, Che L, Ribback S, Dombrowski F, Zhao D, Chen X. Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development. Oncotarget. 2017 Sep 26; 8(43):73433-73447. PMID: 29088718.
      View in: PubMed
    7. Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, Hu J, Chen B, Dong M, Pilo MG, Cigliano A, Evert K, Ribback S, Dombrowski F, Pascale RM, Cossu A, Vidili G, Porcu A, Simile MM, Pes GM, Giannelli G, Gordan J, Wei L, Evert M, Cong W, Calvisi DF, Chen X. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. J Hepatol. 2017 12; 67(6):1194-1203. PMID: 28733220.
      View in: PubMed
    8. Méndez-Lucas A, Li X, Hu J, Che L, Song X, Jia J, Wang J, Xie C, Driscoll PC, Tschaharganeh DF, Calvisi DF, Yuneva M, Chen X. Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities. Cancer Res. 2017 08 15; 77(16):4355-4364. PMID: 28630053.
      View in: PubMed
    9. Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, Cigliano A, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Tao J, Calvisi DF, Chen L, Chen X. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Hepatology. 2017 07; 66(1):167-181. PMID: 28370287.
      View in: PubMed
    10. Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle. 2017 Mar 19; 16(6):499-507. PMID: 28118080.
      View in: PubMed
    11. Che L, Fan B, Pilo MG, Xu Z, Liu Y, Cigliano A, Cossu A, Palmieri G, Pascale RM, Porcu A, Vidili G, Serra M, Dombrowski F, Ribback S, Calvisi DF, Chen X. Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. Oncogenesis. 2016 Dec 05; 5(12):e274. PMID: 27918553.
      View in: PubMed
    12. Cao D, Song X, Che L, Li X, Pilo MG, Vidili G, Porcu A, Solinas A, Cigliano A, Pes GM, Ribback S, Dombrowski F, Chen X, Li L, Calvisi DF. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver Int. 2017 01; 37(1):80-89. PMID: 27264722.
      View in: PubMed
    13. Li L, Che L, Wang C, Blecha JE, Li X, VanBrocklin HF, Calvisi DF, Puchowicz M, Chen X, Seo Y. [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Mol Imaging Biol. 2016 06; 18(3):360-7. PMID: 26567114.
      View in: PubMed
    14. Li L, Che L, Tharp KM, Park HM, Pilo MG, Cao D, Cigliano A, Latte G, Xu Z, Ribback S, Dombrowski F, Evert M, Gores GJ, Stahl A, Calvisi DF, Chen X. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology. 2016 06; 63(6):1900-13. PMID: 26910791.
      View in: PubMed
    15. Hu J, Che L, Li L, Pilo MG, Cigliano A, Ribback S, Li X, Latte G, Mela M, Evert M, Dombrowski F, Zheng G, Chen X, Calvisi DF. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Sci Rep. 2016 Feb 09; 6:20484. PMID: 26857837.
      View in: PubMed
    16. Wang C, Che L, Hu J, Zhang S, Jiang L, Latte G, Demartis MI, Tao J, Gui B, Pilo MG, Ribback S, Dombrowski F, Evert M, Calvisi DF, Chen X. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade. Liver Int. 2016 08; 36(8):1176-86. PMID: 26716908.
      View in: PubMed
    17. Li L, Pilo GM, Li X, Cigliano A, Latte G, Che L, Joseph C, Mela M, Wang C, Jiang L, Ribback S, Simile MM, Pascale RM, Dombrowski F, Evert M, Semenkovich CF, Chen X, Calvisi DF. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J Hepatol. 2016 Feb; 64(2):333-341. PMID: 26476289.
      View in: PubMed
    18. Chen DG, Lin F, Chen XJ, Tang W, Kitzman H. Cusp catastrophe model: a nonlinear model for health outcomes in nursing research. Nurs Res. 2014 May-Jun; 63(3):211-20. PMID: 24785249.
      View in: PubMed
    19. Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol. 2014 Apr; 184(4):912-923. PMID: 24480331.
      View in: PubMed